The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time one of the allergens ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

The eosinophilic esophagitis market is steadily growing, driven by a higher awareness of the condition and improved diagnostic methods. An increase in the number of treatment options, particularly ...

Learn why 90% of the Fortune 100 use GitHub to build, scale, and deliver secure software. Start your journey with GitHub Building great software is a big challenge, and development teams rely on the ...

The problem of economic development in the Global South remains as important as ever. For centuries thinkers have tried to explain why some countries grow rich while others remain poor, with varied ...

In addition, peak eosinophil counts should be quantified ... normalizing growth and development in children, maintaining nutrition, and preventing complications such as food impaction or perforation.

Starting out on the app development journey can reveal an overwhelming number of development options. But with the right app development process to hand, it’s much easier. In this research piece, ...

How much does it cost to make an app? Likely, a price tag to build an app is one of the first pieces of information that app brands and developers need to know, when they launch an app development ...

EO, eosinophils; DC, dendritic cells; M2, M2 macrophages ... The previously mentioned molecular mechanisms endorse the rationale for the development of biologic drugs with targets shared by multiple ...

Etrasimod is under clinical development by Pfizer and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase ...